Durvalumab-Induced Immune Thrombocytopenia in Patients with Advanced Cholangiocarcinoma Undergoing Yttrium-90 Radioembolization

Durvalumab-Induced Immune Thrombocytopenia in Patients with Advanced Cholangiocarcinoma Undergoing Yttrium-90 Radioembolization

Introduction: Immune thrombocytopenia (ITP) secondary to durvalumab, a programmed cell death ligand 1 inhibitor, is a rare but clinically significant immune-related adverse event. Herein, we present 2 patients with cholangiocarcinoma who developed ITP immediately post-yttrium-90 radioembolization (Y...

Full description

Saved in:
Bibliographic Details
Main Authors: Maaz Khan Afghan, Areeb Lutfi, Fatima Qadri, Sahrish Khan, Sana Javaid, Brian Michael Currie, Juan Pablo Rocca, Benjamin Samstein, Erika Hissong, Pashtoon Murtaza Kasi
Format: Article
Language:English
Published: Karger Publishers 2024-10-01
Series:Case Reports in Oncology
Subjects:
cholangiocarcinoma
durvalumab
immune thrombocytopenia
yttrium-90
Online Access:https://beta.karger.com/Article/FullText/541550
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://beta.karger.com/Article/FullText/541550

Similar Items